Allergan receives US antitrust clearance to buy Kythera Biopharmaceuticals
Allergan has received antitrust approval to acquire Kythera Biopharmaceuticals for $2.1 billion, according to a list released by the Federal Trade Commission on Monday. The deal received clearance through the 'early-termination'...To view the full article, register now.
Already a subscriber? Click here to view full article